Acumen Pharmaceuticals, Inc. (ABOS) NASDAQ
2.37
-0.14(-5.58%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Acumen Pharmaceuticals, Inc.
Address
427 Park Street
Newton, VA 22902
United States of America (the)
Phone
434 297 1000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
61
First IPO Date
July 01, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Daniel J. O'Connell | Chief Executive Officer & Director | 972,747 | 1970 |
| Caleb E. Finch | Co-Founder | 42,000 | N/A |
| William L. Klein | Co-Founder | 42,000 | N/A |
| Grant A. Krafft | Co-Founder | 42,000 | N/A |
| Russell Barton | Chief Operating Officer | 223,680 | 1959 |
| Matt Zuga | Chief Financial Officer & Chief Business Officer | 681,780 | N/A |
| Derek Meisner | Chief Legal Officer & Corporate Secretary | 752,945 | 1971 |
| James Doherty | President & Chief Development Officer | 764,370 | 1968 |
| Alex Braun | Vice President & Head of Investor Relations | 0 | N/A |
| Kelly Carranza | Senior Vice President of Finance & Accounting and Corporate Controller | 0 | N/A |
| Siew Tin Gan | Assistant Vice President & Head of Clinical Operations | 0 | N/A |
| Julie Bockenstette | Chief People Officer | 0 | N/A |
| Robyn Moxon | Associate Director of Communications | 0 | N/A |
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
